• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Contemporary utilization of GLP1 receptor agonists and SGLT2 inhibitors in patients with diagnosed type 2 diabetes and cardiovascular disease in the United States.

作者信息

Al-Kindi Sadeer G, Janus Scott E, Neeland Ian J, Rajagopalan Sanjay

机构信息

Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA), Harrington Heart and Vascular Institute, University Hospitals, Cleveland, OH 44124, United States of America; Case Western Reserve University, Cleveland, OH, United States of America.

Center for Integrated and Novel Approaches in Vascular-Metabolic Disease (CINEMA), Harrington Heart and Vascular Institute, University Hospitals, Cleveland, OH 44124, United States of America; Case Western Reserve University, Cleveland, OH, United States of America.

出版信息

J Diabetes Complications. 2022 Jul;36(7):108224. doi: 10.1016/j.jdiacomp.2022.108224. Epub 2022 Jun 1.

DOI:10.1016/j.jdiacomp.2022.108224
PMID:35667964
Abstract
摘要

相似文献

1
Contemporary utilization of GLP1 receptor agonists and SGLT2 inhibitors in patients with diagnosed type 2 diabetes and cardiovascular disease in the United States.美国2型糖尿病合并心血管疾病患者中胰高血糖素样肽1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂的当代应用情况
J Diabetes Complications. 2022 Jul;36(7):108224. doi: 10.1016/j.jdiacomp.2022.108224. Epub 2022 Jun 1.
2
Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.糖尿病合并心血管疾病患者中 SGLT2-i 与 GLP1-RA 的合理选择策略。
Curr Cardiol Rep. 2019 Jul 27;21(9):100. doi: 10.1007/s11886-019-1197-6.
3
Cardiovascular benefits of SGLT2 inhibitors and GLP-1 receptor agonists in Type 2 diabetes.钠-葡萄糖协同转运蛋白2抑制剂和胰高血糖素样肽-1受体激动剂对2型糖尿病患者的心血管益处。
Med Lett Drugs Ther. 2019 Feb 25;61(1566):26-28.
4
Should We Be Combining GLP-1 Receptor Agonists and SGLT2 Inhibitors in Treating Diabetes?在治疗糖尿病时，我们应该联合使用GLP-1受体激动剂和SGLT2抑制剂吗？
Am J Med. 2018 May;131(5):461-463. doi: 10.1016/j.amjmed.2017.11.052. Epub 2018 Jan 5.
5
Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的心血管疗效和安全性：系统评价和网络荟萃分析。
Diabet Med. 2019 Apr;36(4):444-452. doi: 10.1111/dme.13898. Epub 2019 Jan 30.
6
Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists versus sodium-glucose cotransporter-2 inhibitors in patients with type 2 diabetes: A population-based cohort study.基于人群队列研究的 2 型糖尿病患者胰高血糖素样肽-1 受体激动剂与钠-葡萄糖共转运蛋白 2 抑制剂的心血管比较效果。
Diabetes Obes Metab. 2022 Aug;24(8):1623-1637. doi: 10.1111/dom.14741. Epub 2022 May 25.
7
Contemporary National Patterns of Eligibility and Use of Novel Cardioprotective Antihyperglycemic Agents in Type 2 Diabetes Mellitus.当代 2 型糖尿病患者新型心脏保护降血糖药物的资格和使用的国家模式。
J Am Heart Assoc. 2021 Jul 6;10(13):e021084. doi: 10.1161/JAHA.121.021084. Epub 2021 May 15.
8
The comparative cardiovascular and renal effectiveness of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: A Scandinavian cohort study.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的心血管和肾脏比较效果：斯堪的纳维亚队列研究。
Diabetes Obes Metab. 2022 Mar;24(3):473-485. doi: 10.1111/dom.14598. Epub 2021 Nov 24.
9
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
10
GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.GLP-1 受体激动剂联合或不联合 SGLT2 抑制剂治疗 2 型糖尿病患者。
J Am Coll Cardiol. 2023 Aug 8;82(6):517-525. doi: 10.1016/j.jacc.2023.05.048.

引用本文的文献

1
Second-year results from CINEMA: A novel, patient-centered, team-based intervention for patients with Type 2 diabetes or prediabetes at high cardiovascular risk.CINEMA研究的第二年结果：一种针对心血管疾病高风险的2型糖尿病或糖尿病前期患者的新型、以患者为中心、基于团队的干预措施。
Am J Prev Cardiol. 2023 Dec 21;17:100630. doi: 10.1016/j.ajpc.2023.100630. eCollection 2024 Mar.